Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.41 |
| ▸ | TPH1 | P17752 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913876 | 0.85 | TAAR1 (0.46) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5914452 | 0.84 | MAPK14 (0.41) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5261647 | 0.84 | NPR3 (0.47) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5913824 | 0.83 | MAPK14 (0.41) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5914396 | 0.82 | KDM4E (0.42) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5264550 | 0.81 | GAA (0.41) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5914170 | 0.80 | ALDH1A1 (0.38) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5914432 | 0.79 | MMP2 (0.42) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5913983 | 0.78 | CYP1A2 (0.36) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5914274 | 0.78 | MAPK14 (0.37) | USP2ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | claimed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | CIT 904/4885AKT1 698/4885USP2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.